🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 12 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/05/2015 54,00 55,37 53,98 55,21 +2,35% 2,57% 960.800
20/05/2015 51,68 54,89 51,32 53,94 +5,58% 6,90% 679.200
19/05/2015 52,48 52,75 50,47 51,09 -1,73% 4,34% 751.500
18/05/2015 52,43 54,24 51,50 51,99 -0,19% 5,23% 1.235.700
15/05/2015 53,41 55,59 51,78 52,09 -4,12% 7,13% 912.100
14/05/2015 55,50 55,65 53,44 54,33 -2,13% 3,98% 347.500
13/05/2015 55,14 56,17 54,63 55,51 +0,98% 2,79% 525.300
12/05/2015 54,38 55,05 53,17 54,97 +0,15% 3,46% 692.300
11/05/2015 54,29 56,79 54,29 54,89 +1,57% 4,60% 684.000
08/05/2015 55,50 57,05 53,82 54,04 -1,98% 5,82% 730.400
07/05/2015 55,35 56,43 53,58 55,13 +0,24% 5,16% 878.400
06/05/2015 54,13 58,83 53,26 55,00 +3,52% 10,29% 1.153.600
05/05/2015 55,50 58,20 52,37 53,13 -12,67% 10,50% 1.991.300
04/05/2015 59,26 61,88 59,20 60,84 +1,64% 4,52% 684.700
01/05/2015 59,47 61,00 58,01 59,86 +1,89% 5,03% 710.600
30/04/2015 62,30 63,15 57,81 58,75 -5,97% 8,57% 1.399.400
29/04/2015 63,94 66,16 61,70 62,48 -3,16% 6,98% 377.200
28/04/2015 65,96 67,30 62,94 64,52 -2,00% 6,61% 538.500
27/04/2015 70,30 70,48 63,37 65,84 -6,58% 10,11% 994.400
24/04/2015 70,89 73,01 70,42 70,48 -1,23% 3,64% 337.900
23/04/2015 74,40 74,40 71,33 71,36 +0,54% 4,13% 884.200
22/04/2015 71,04 72,31 69,53 70,98 +0,00% 3,91% 528.500
21/04/2015 69,67 71,49 69,50 70,98 +2,19% 2,86% 408.600
20/04/2015 71,57 71,91 69,10 69,46 -1,81% 3,92% 491.400
17/04/2015 70,46 71,97 69,60 70,74 -0,35% 3,36% 685.300
16/04/2015 70,16 72,93 68,85 70,99 +5,40% 5,81% 1.180.500
15/04/2015 69,42 69,73 66,55 67,35 -2,52% 4,58% 504.900
14/04/2015 71,30 72,14 69,01 69,09 -2,85% 4,38% 381.900
13/04/2015 72,11 73,94 70,66 71,12 -0,75% 4,55% 466.600
10/04/2015 71,94 72,71 69,63 71,66 -0,15% 4,28% 470.200